$11.11
-0.36[-3.14%]
At close: May 23
$11.11
0[0.00%]
After Hours: 4:00PM EDT
EyePoint Pharmaceuticals
(NASDAQ:EYPT)EyePoint Pharmaceuticals Stock (NASDAQ:EYPT), Analyst Ratings, Price Targets, Predictions
EyePoint Pharmaceuticals Inc has a consensus price target of $35.22, established from looking at the 33 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Baird, and Chardan Capital on May 13, 2024, May 8, 2024, and May 7, 2024. With an average price target of $32 between HC Wainwright & Co., Baird, and Chardan Capital, there's an implied 188.03% upside for EyePoint Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Baird
Chardan Capital
Mizuho
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for EyePoint Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2024 | Buy Now | 170.03% | HC Wainwright & Co. | Yi Chen | $33 → $30 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 242.03% | Baird | — | $46 → $38 | Maintains | Outperform | Get Alert |
| 05/07/2024 | Buy Now | 152.03% | Chardan Capital | Daniil Gataulin | $39 → $28 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 170.03% | Mizuho | Graig Suvannavejh | $39 → $30 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 197.03% | HC Wainwright & Co. | Yi Chen | $33 → $33 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 251.04% | Mizuho | Graig Suvannavejh | $30 → $39 | Maintains | Buy | Get Alert |
| 01/22/2024 | Buy Now | 215.03% | JP Morgan | Tessa Romero | → $35 | Initiates | → Overweight | Get Alert |
| 01/16/2024 | Buy Now | 197.03% | HC Wainwright & Co. | Yi Chen | $35 → $33 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | 296.04% | Capital One | Zegbeh Jallah | → $44 | Initiates | → Overweight | Get Alert |
| 12/07/2023 | Buy Now | 170.03% | Mizuho | Graig Suvannavejh | $20 → $30 | Maintains | Buy | Get Alert |
| 12/05/2023 | Buy Now | 215.03% | HC Wainwright & Co. | Yi Chen | $25 → $35 | Maintains | Buy | Get Alert |
| 11/02/2023 | Buy Now | 125.02% | HC Wainwright & Co. | Yi Chen | $27 → $25 | Maintains | Buy | Get Alert |
| 11/02/2023 | Buy Now | 80.02% | Mizuho | Graig Suvannavejh | → $20 | Initiates | → Buy | Get Alert |
| 09/14/2023 | Buy Now | 179.03% | Cantor Fitzgerald | Jennifer Kim | → $31 | Reiterates | Overweight → Overweight | Get Alert |
| 09/12/2023 | Buy Now | 143.02% | HC Wainwright & Co. | Yi Chen | → $27 | Reiterates | Buy → Buy | Get Alert |
| 08/31/2023 | Buy Now | 179.03% | Cantor Fitzgerald | Jennifer Kim | → $31 | Reiterates | Overweight → Overweight | Get Alert |
| 08/03/2023 | Buy Now | 143.02% | HC Wainwright & Co. | Yi Chen | → $27 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | Buy Now | 98.02% | Chardan Capital | Daniil Gataulin | → $22 | Reiterates | Buy → Buy | Get Alert |
| 07/28/2023 | Buy Now | 143.02% | HC Wainwright & Co. | Yi Chen | → $27 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2023 | Buy Now | 179.03% | Cantor Fitzgerald | Jennifer Kim | → $31 | Reiterates | Overweight → Overweight | Get Alert |
| 06/14/2023 | Buy Now | 134.02% | JonesTrading | Sean Kim | → $26 | Initiates | → Buy | Get Alert |
| 06/06/2023 | Buy Now | 143.02% | HC Wainwright & Co. | Yi Chen | → $27 | Reiterates | Buy → Buy | Get Alert |
| 05/19/2023 | Buy Now | 143.02% | HC Wainwright & Co. | Yi Chen | $25 → $27 | Maintains | Buy | Get Alert |
| 05/19/2023 | Buy Now | 98.02% | Chardan Capital | Daniil Gataulin | $21 → $22 | Maintains | Buy | Get Alert |
| 05/18/2023 | Buy Now | 395.05% | Guggenheim | Yatin Suneja | $52 → $55 | Maintains | Buy | Get Alert |
| 03/27/2023 | Buy Now | 125.02% | HC Wainwright & Co. | Yi Chen | → $25 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | 89.02% | Chardan Capital | Daniil Gataulin | → $21 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | 125.02% | HC Wainwright & Co. | Yi Chen | → $25 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 125.02% | HC Wainwright & Co. | Yi Chen | → $25 | Reiterates | → Buy | Get Alert |
| 11/11/2022 | Buy Now | 368.05% | Guggenheim | Yatin Suneja | $60 → $52 | Maintains | Buy | Get Alert |
FAQ
What is the target price for EyePoint Pharmaceuticals (EYPT)?
The latest price target for EyePoint Pharmaceuticals (NASDAQ: EYPT) was reported by HC Wainwright & Co. on May 13, 2024. The analyst firm set a price target for $30.00 expecting EYPT to rise to within 12 months (a possible 170.03% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for EyePoint Pharmaceuticals (EYPT)?
The latest analyst rating for EyePoint Pharmaceuticals (NASDAQ: EYPT) was provided by HC Wainwright & Co., and EyePoint Pharmaceuticals maintained their buy rating.
When was the last upgrade for EyePoint Pharmaceuticals (EYPT)?
There is no last upgrade for EyePoint Pharmaceuticals.
When was the last downgrade for EyePoint Pharmaceuticals (EYPT)?
There is no last downgrade for EyePoint Pharmaceuticals.
When is the next analyst rating going to be posted or updated for EyePoint Pharmaceuticals (EYPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of EyePoint Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for EyePoint Pharmaceuticals was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.
Is the Analyst Rating EyePoint Pharmaceuticals (EYPT) correct?
While ratings are subjective and will change, the latest EyePoint Pharmaceuticals (EYPT) rating was a maintained with a price target of $33.00 to $30.00. The current price EyePoint Pharmaceuticals (EYPT) is trading at is $11.11, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.